Skip to main content

Over and Under-Treatment of Diabetes

By September 25, 2017Commentary2 min read

Much of the discussion of excessive health spending in the US has focused on supposed inappropriate or unnecessary medical treatments.  But under-treatment clearly also exists.  Diabetes is an interesting case study because over-treatment can lead to serious adverse events, as can under-treatment.  Research in the Journal of General Internal Medicine used data on Medicare beneficiaries to identify rates of under and over-treatment of diabetes and to examine whether over-treatment was frequently de-intensified.   (JGIM Article)   The data was from 2010 and 2011 and included actual lab values from tests as well as all drugs prescribed, the most common treatment for diabetes.  Over-treatment was defined by use of certain medications by patients with HbA1c values under a certain level (the level was set very conservatively, so over-treatment was likely under-identified).  Under-treated patients were those with an HbA1c value over a certain level, regardless of medications used.  For patients who were initially categorized as over-treated, a further analysis was done to see if their medications were adjusted to prevent this over-treatment.  The final study group consisted of about 79,000 beneficiaries.

Of these, 10.8% were categorized as over-treated and 6.9% as under-treated.  Over-treatment was most likely for dual eligibles and beneficiaries over 75.  Among the over-treated group, only 14% had their therapies de-intensified.  Guidelines for diabetes treatment are a work in progress, and in recent years, they have been adjusted to encourage less aggressive blood sugar control in many cases.  There may be less over-treatment now than there was during the study period.  No specific cost analysis was performed by the authors, but if the rates of over-treatment and under-treatment found in the study are close to accurate, then if all patients got treatment by the guidelines, you would suspect that their would be a net savings to the system, both from lower drug costs and treatment of fewer adverse events.  This is encouraging. Diabetes accounts for a fair amount of health spending, so the savings could be meaningful.

Kevin Roche

Author Kevin Roche

The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry through Roche Consulting, LLC. Mr. Roche is available to assist health care companies through consulting arrangements and may be reached at khroche@healthy-skeptic.com.

More posts by Kevin Roche

Leave a comment